<DOC>
	<DOC>NCT00547261</DOC>
	<brief_summary>The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.</brief_summary>
	<brief_title>Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer</brief_title>
	<detailed_description />
	<criteria>Diagnosis of metastatic or locally advanced nonhematological cancer Patients with solid tumors refractory to therapy or for whom no therapy exists Five or more prior chemotherapy lines for metastatic disease Eastern Cooperative Oncology Group (ECOG) performance status &gt;2 Patients having discontinued previous specific anticancer treatment Patients who have not recovered from all toxic effects from previous specific anticancer treatment (excluding alopecia) Patients with abnormal biological/hematological parameters, cardiac abnormalities or serious infection/intercurrent illness likely to jeopardize the patient's safety or the course of the protocol treatment No adequate birth control methods The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>antimitotic</keyword>
	<keyword>tubulin binder</keyword>
</DOC>